tutorial

Gastroesophageal Junction Adenocarcinoma Care Tech Platform Monitoring Guide 2026

"A comprehensive guide to monitoring digital health platforms supporting GEJ adenocarcinoma care, covering Siewert classification routing to surgical approach decision engines, HER2 and PD-L1 biomarker dashboards, perioperative chemotherapy regimen monitoring, nutritional surveillance post-resection, and Barrett's surveillance in survivors."

Gastroesophageal Junction Adenocarcinoma Care Tech Platform Monitoring Guide 2026

Overview

Gastroesophageal junction (GEJ) adenocarcinoma is defined as adenocarcinoma arising within 5 centimeters proximal or distal to the anatomic gastroesophageal junction. The Siewert classification system — developed to guide surgical approach — divides these tumors into three types: Siewert I (distal esophageal, 1–5 cm above the GEJ), Siewert II (true carcinoma of the cardia, 1 cm above to 2 cm below the GEJ), and Siewert III (subcardial gastric cancer, 2–5 cm below the GEJ). This classification has profound clinical implications: Siewert I tumors are generally managed as esophageal cancers with Ivor Lewis or transhiatal esophagectomy, while Siewert II–III tumors trend toward gastric-approach surgery (total gastrectomy with D2 lymphadenectomy) and follow gastric cancer perioperative chemotherapy protocols.

The molecular landscape of GEJ adenocarcinoma reveals two targetable subgroups that are routinely tested at diagnosis. Approximately 15–20% of tumors overexpress HER2 (IHC 3+ or IHC 2+/FISH-positive), qualifying patients for trastuzumab added to first-line platinum-fluoropyrimidine chemotherapy — the ToGA regimen that remains a standard of care. PD-L1 combined positive score (CPS) ≥ 5 qualifies patients for nivolumab added to FLOT or FOLFOX chemotherapy in the perioperative or first-line metastatic setting, per CheckMate 649 and KEYNOTE-859 data. In the localized resectable setting, the dominant perioperative regimen is FLOT (docetaxel, oxaliplatin, leucovorin, 5-FU), which has supplanted ECF/ECX for fit patients, while CROSS chemoradiation (carboplatin/paclitaxel + radiation) remains standard in esophagus-dominant Siewert I disease.

Care technology platforms supporting GEJ adenocarcinoma must coordinate a more complex multi-disciplinary workflow than most gastrointestinal malignancies: Siewert classification routing to surgery approach decision engines, HER2 and PD-L1 biomarker result dashboards, perioperative chemotherapy adherence and toxicity monitoring, nutritional surveillance in the post-resection period (including B12, iron, and reflux complication tracking), and Barrett's esophagus surveillance programs for survivors who may retain at-risk esophageal mucosa.

Care Technology Landscape

Staging and Classification Data Systems — GEJ adenocarcinoma staging combines endoscopic ultrasound (EUS) T-staging, CT chest/abdomen/pelvis for nodal and metastatic assessment, and diagnostic laparoscopy for peritoneal staging in locally advanced disease. The Siewert type assigned by the gastroenterologist or surgeon at endoscopy and CT review must be captured as a structured field in the EHR and propagated to both the surgical scheduling system and the oncology information system (OIS), where it drives treatment protocol assignment.

Biomarker Testing and Routing Platforms — HER2 IHC and FISH, PD-L1 CPS scoring, and mismatch repair (MMR) status are now routinely tested at GEJ adenocarcinoma diagnosis. Laboratory information systems must route these results to structured fields in the OIS and trigger CDS alerts when actionable results (HER2 3+, PD-L1 CPS ≥ 5, MSI-H) are available. Reflex testing logic — IHC 2+ reflexing automatically to FISH — must be built into the LIS order logic.

Perioperative Chemotherapy Management Platforms — FLOT requires careful hematologic monitoring (neutropenia, thrombocytopenia), peripheral neuropathy surveillance, and dose modification algorithms. Pharmacy management systems (PharmaNet, Mediware, or Epic Beacon) must support FLOT dosing calculations, cycle scheduling, and automated growth factor (G-CSF) order triggers when neutropenia risk exceeds protocol thresholds.

Nutritional Surveillance and Deficiency Monitoring — Post-esophagectomy or post-gastrectomy patients require lifelong nutritional monitoring: total gastrectomy eliminates intrinsic factor production, leading to B12 deficiency; iron absorption is impaired by bypass of the proximal small bowel; postgastrectomy syndrome (dumping, reflux, early satiety) affects caloric intake. Nutritional surveillance platforms must schedule labs (B12, CBC, ferritin, folate, vitamin D) at protocol-defined intervals and route low results to registered dietitian (RD) and oncology workflow queues.

Barrett's Esophagus Surveillance Systems — Patients treated with esophagus-sparing approaches for Siewert II–III disease, or those with known Barrett's at diagnosis, require endoscopic surveillance for metachronous lesions. Endoscopy scheduling systems must maintain Barrett's surveillance protocols, generate outreach at appropriate intervals (every 3–5 years for non-dysplastic Barrett's), and link biopsy results to the oncology encounter.

Key Monitoring Metrics

Siewert Classification and Surgical Approach Routing

Data Capture Quality

  • Siewert type captured as a structured field (not free text) in endoscopy and surgical notes: compliance rate (target: > 95%)
  • Siewert type populated in OIS at time of treatment planning encounter: completion rate
  • Discordance between endoscopist-assigned and surgeon-assigned Siewert type triggering MDT review: flag rate

Surgical Approach Decision Support

  • Siewert I cases routed to esophagectomy surgical scheduling track: routing accuracy rate
  • Siewert II–III cases routed to gastrectomy surgical scheduling track: routing accuracy rate
  • MDT review documented for all Siewert II cases (surgically ambiguous): MDT entry rate (target: 100%)
  • Time from MDT decision to surgical scheduling: target ≤ 5 business days

Cross-Team Protocol Assignment

  • Siewert I cases assigned CROSS chemoradiation protocol in OIS (when esophageal approach): protocol assignment accuracy
  • Siewert II–III cases assigned FLOT perioperative protocol in OIS (when gastric approach): protocol assignment accuracy
  • Cases with HER2+ result automatically generating trastuzumab addition flag in treatment protocol: trigger rate

HER2 and PD-L1 Biomarker Dashboards

Testing Completeness

  • HER2 IHC ordered on all newly diagnosed GEJ adenocarcinoma specimens: order completeness (target: 100%)
  • PD-L1 CPS testing ordered on all newly diagnosed GEJ adenocarcinoma specimens: order completeness (target: 100%)
  • MMR/MSI testing ordered at diagnosis: order completeness (target: 100%)
  • IHC 2+ results automatically generating FISH reflex order: reflex automation rate (target: 100%)

Result Routing and Latency

  • HER2 result (IHC/FISH) routed to OIS structured biomarker field within 4 hours of sign-out: routing rate
  • PD-L1 CPS result routed to OIS within 4 hours of sign-out: routing rate
  • Time from biospecimen receipt to HER2 IHC final result: target ≤ 5 business days; FISH ≤ 7 business days

CDS Action Triggers

  • HER2 IHC 3+ or FISH-positive triggering trastuzumab addition CDS alert: trigger rate (target: 100%)
  • PD-L1 CPS ≥ 5 triggering nivolumab addition CDS alert: trigger rate (target: 100%)
  • MSI-H result triggering pembrolizumab and/or PD-1 first-line CDS alert: trigger rate (target: 100%)
  • CDS alert to oncologist acknowledged within 2 business days: acknowledgment rate

Perioperative FLOT Chemotherapy Monitoring

Hematologic Surveillance

  • CBC with differential resulted within 48 hours before each FLOT cycle: pre-cycle lab compliance (target: > 95%)
  • ANC < 1.0 × 10⁹/L detected before cycle triggering delay decision alert: detection rate
  • Platelet count < 75 × 10⁹/L before cycle triggering dose modification alert: detection rate
  • Febrile neutropenia episodes with G-CSF secondary prophylaxis order placed within 24 hours of episode: order compliance

Neurotoxicity Tracking

  • Peripheral neuropathy PRO survey completed each cycle: completion rate (target: > 85%)
  • Grade ≥ 2 neuropathy triggering oxaliplatin dose reduction CDS: trigger rate (target: 100%)
  • Cumulative oxaliplatin dose documented and flagged when approaching 850 mg/m²: tracking rate

Cycle Adherence

  • FLOT cycles delivered on schedule (within ±7 days of planned date): on-time delivery rate (target: > 90%)
  • Dose delays > 14 days from planned date triggering oncologist review: escalation rate
  • Pre-op surgery scheduled within 28 days of last planned pre-operative cycle: scheduling compliance

Nutritional Surveillance Post-Resection

Laboratory Monitoring

  • B12 level checked at 6 months and annually post-total gastrectomy: order compliance (target: > 90%)
  • Iron studies (serum iron, ferritin, TIBC) checked at 6 months and annually: order compliance
  • Folate and vitamin D checked at 12 months post-resection: order compliance
  • B12 < 200 pg/mL triggering B12 replacement order or dietitian referral: CDS trigger rate

Dietitian Referral and Visit Tracking

  • Registered dietitian referral placed within 30 days of surgical discharge: referral rate (target: > 85%)
  • Post-discharge dietitian visit completed within 60 days: visit completion rate
  • Weight loss > 10% from pre-operative baseline at 3-month post-op visit triggering intensified nutritional support: alert rate

Reflux and Dumping Surveillance

  • Patients with Siewert I treated with esophagectomy: GERD symptom PRO survey at 3 and 12 months
  • Severe dumping syndrome (≥ grade 2 by PRO) triggering dietitian and gastroenterology referral: cascade order rate
  • Endoscopy with anastomotic assessment scheduled at 1 year post-esophagectomy: scheduling compliance

Barrett's Esophagus Surveillance in Survivors

Protocol Configuration

  • Barrett's esophagus surveillance schedule encoded for all patients with known Barrett's at diagnosis: protocol creation rate
  • Surveillance interval set per Prague Classification and dysplasia grade: protocol accuracy audit
  • Esophagus-sparing resection cases (select Siewert II) with residual at-risk segment flagged for endoscopic follow-up: flag rate

Outreach and Completion

  • Endoscopy surveillance appointment scheduled before due date: on-time scheduling rate (target: > 85%)
  • Patients overdue for Barrett's surveillance by > 60 days: automated outreach trigger rate
  • Biopsy results from surveillance endoscopy linked to oncology encounter within 5 business days: linkage rate

Dysplasia Detection Response

  • High-grade dysplasia detected on surveillance triggering MDT review within 10 business days: escalation rate
  • New adenocarcinoma detected in Barrett's surveillance triggering restaging CT within 14 days: cascade order rate

Platform Setup

Observability Architecture for GEJ Platforms

# Prometheus scrape config for GEJ adenocarcinoma care platforms
scrape_configs:
  - job_name: siewert_classification_router
    static_configs:
      - targets: ['siewert-router.internal:9090']
    scrape_interval: 60s

  - job_name: her2_pdl1_biomarker_router
    static_configs:
      - targets: ['biomarker-router.internal:9090']
    scrape_interval: 30s

  - job_name: flot_chemo_management
    static_configs:
      - targets: ['chemo-platform.internal:9090']
    scrape_interval: 60s

  - job_name: nutritional_surveillance
    static_configs:
      - targets: ['nutrition-platform.internal:9090']
    scrape_interval: 300s

  - job_name: barretts_surveillance_scheduler
    static_configs:
      - targets: ['endoscopy-sched.internal:9090']
    scrape_interval: 300s

Biomarker Routing Canary

Validate HER2 result routing end-to-end:

# Pseudocode: HER2 routing canary
def run_her2_routing_canary():
    test_patient_id = "CANARY-GEJ-HER2-001"
    # Inject synthetic HER2 IHC 3+ result
    inject_biomarker_result(
        patient_id=test_patient_id,
        test="HER2_IHC",
        result="3+",
        tumor_type="GEJ_adenocarcinoma"
    )
    start = time.now()
    # Check OIS structured field populated
    ois_field = poll_for_ois_field(
        patient_id=test_patient_id,
        field="her2_status",
        timeout=14400  # 4 hours
    )
    latency = time.now() - start
    metrics.record("her2_routing_latency_seconds", latency)
    if ois_field is None:
        page_on_call("GEJ canary: HER2 IHC result not routed to OIS within 4-hour SLA")
    # Check CDS alert generated
    cds_alert = check_cds_alert(test_patient_id, alert_type="trastuzumab_addition")
    if not cds_alert:
        alert_informatics_team("GEJ canary: trastuzumab CDS alert not generated for HER2 3+ patient")

FLOT Pre-Cycle Lab Automation

-- Ensure pre-cycle CBC is ordered for FLOT patients
CREATE OR REPLACE PROCEDURE check_flot_precycle_labs(patient_id UUID, cycle_date DATE)
AS $$
BEGIN
  -- Flag if CBC not resulted within 48h before cycle_date
  IF NOT EXISTS (
    SELECT 1 FROM lab_results
    WHERE patient_id = patient_id
      AND test_code = 'CBC_DIFF'
      AND result_date BETWEEN cycle_date - INTERVAL '2 days' AND cycle_date
  ) THEN
    INSERT INTO clinical_alerts (patient_id, alert_type, severity, message, created_at)
    VALUES (patient_id, 'FLOT_PRECYCLE_LAB_MISSING', 'P2',
            'CBC not resulted within 48h before scheduled FLOT cycle', NOW());
  END IF;
END;
$$ LANGUAGE plpgsql;

Run this procedure nightly for all FLOT patients with a cycle date within the next 3 days.

Nutritional Deficiency Alert Configuration

# Pseudocode: nutritional lab monitoring for post-gastrectomy patients
NUTRITIONAL_THRESHOLDS = {
    "B12": {"low": 200, "unit": "pg/mL", "action": "b12_replacement_referral"},
    "FERRITIN": {"low": 12, "unit": "ng/mL", "action": "iron_supplementation_referral"},
    "VIT_D": {"low": 20, "unit": "ng/mL", "action": "vitamin_d_supplementation"},
    "FOLATE": {"low": 2.0, "unit": "ng/mL", "action": "folate_supplementation"},
}

def monitor_nutritional_labs(patient_id):
    for lab_test, threshold in NUTRITIONAL_THRESHOLDS.items():
        result = get_latest_lab(patient_id, lab_test)
        if result and result.value < threshold["low"]:
            generate_cds_alert(
                patient_id=patient_id,
                alert_type=threshold["action"],
                lab_test=lab_test,
                value=result.value,
                threshold=threshold["low"]
            )

Alerting Strategies

Severity Tiering

P1 — Immediate Clinical Impact

  • Biomarker routing engine down; HER2 or PD-L1 results not reaching OIS or CDS
  • Siewert classification routing system offline; surgical approach decision engine not receiving structured type
  • FLOT chemotherapy management platform down; cycle scheduling and dose-hold decisions not processing
  • ANC critical value (< 0.5 × 10⁹/L) for FLOT patient not generating alert within 2 hours of result

P2 — Degraded Operation

  • HER2 IHC result routing latency > 8 hours from sign-out
  • FLOT pre-cycle lab compliance < 90% week-over-week
  • Nutritional lab order compliance < 80% for post-gastrectomy patients at 6-month follow-up
  • Barrett's surveillance scheduling failure rate > 5% of due-date cohort

P3 — Quality and Compliance

  • Siewert type captured as free text rather than structured field in > 5% of cases: template issue
  • IHC 2+ reflex to FISH automation failure > 2%: LIS configuration audit
  • Post-resection B12 monitoring protocol not applied to total gastrectomy patients: registry gap report

On-Call Escalation

  • Clinical informatics engineer (primary for P1 routing and platform failures)
  • Oncology pharmacist on call (FLOT dose-hold decisions out of hours)
  • GI surgery APP on call (for Siewert routing and surgical scheduling P1 escalations)

Notification Channels

  • P1: PagerDuty page + SMS to primary and secondary on-call
  • P2: Slack #gej-informatics + email to GI oncology informatics lead
  • P3: Automated JIRA ticket to oncology informatics backlog; monthly nutritional compliance report to MDT coordinator

Conclusion

Gastroesophageal junction adenocarcinoma occupies a clinically demanding intersection between esophageal and gastric oncology, requiring care technology platforms to manage anatomic ambiguity (Siewert classification routing), molecular precision (HER2 and PD-L1 biomarker dashboards), perioperative chemotherapy toxicity surveillance, and lifelong nutritional and endoscopic follow-up. The consequences of platform failure in this disease — a missed HER2 3+ result that delays trastuzumab initiation, a Siewert type routed to the wrong surgical protocol, a B12 deficiency uncaught for two years after total gastrectomy — are measurable in patient outcomes.

Engineering teams supporting GEJ adenocarcinoma programs should prioritize biomarker routing canary tests, automated FLOT pre-cycle lab compliance checks, and nutritional deficiency monitoring pipelines for post-resection patients. With observability infrastructure tuned to GEJ's specific multi-step clinical workflow, care technology becomes a reliable backbone for one of the most complex gastrointestinal oncology programs in 2026.

Monitor your app with Vigilmon

Free plan — 5 monitors, no credit card required. Up and running in 60 seconds.

Start free →
← Back to all articles